Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

(2017) Isabelle Malet et al.   mBio

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study*

(2016) Danielle P. Porter et al.   HIV CLINICAL TRIALS

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection

(2016) J. Ambrosioni et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'

(2014) C. Amiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance

(2014) Soundasse Munir et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses

(2013) S. Lambert-Niclot et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen

(2009) J. Ghosn et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

(2009) Erik Serrao et al.   Retrovirology

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

(2008) I. Malet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY